Leadership

Co-Founder and Chief Executive Officer

Jeff He is the Co-Founder & CEO at TandemAI. He brings 20+ year leadership experience in corporate strategy, business development, venture financing and operation.

Previously, Jeff co-founded HiFiBiO Therapeutics and served as its Chief Operating Officer since 2017. Prior to that, Jeff was co-founder & CFO at Harbour BioMed from 2015 to 2017. Before launching his entrepreneurial career, Jeff served as Executive Vice President of Strategy and Operation at ShangPharma/ChemPartner for 3 years. Mr. He also served as Senior Vice President at Texas Pacific Group (TPG), where he helped to privatize ShangPharma from the NYSE. Prior to TPG, Mr. He held management roles with increasing P&L responsibilities at Danaher/Fluke and Saint-Gobain. In his early career, he was a strategy consultant at Bain & Company and a senior financial analyst at Intel.

Mr. He received his MBA degree from Goizueta Business School at Emory University, M.S. degree in Economics from Shanghai Univ. of Science and Technology, and bachelor degree in engineering from Zhejiang University.

Co-Founder and Chief Operations Officer

Dr. Tang is the Co-Founder & COO at TandemAI. He brings 26+ years of research and leadership experience to the company.

Formerly Dr. Tang worked at Shanghai ChemPartner from 2012 to 2021. During the last 5 years at ChemPartner, he initially served as the President and then the CEO managing over 2,000 scientific staff and delivered double-digit annual revenue growth in the research service business. Prior to ChemPartner, Dr. Tang spent 16 years at Merck with increasing scientific and managerial responsibilities. His last position at Merck was as Distinguished Senior Investigator. He also served as co-chairs of multiple early development programs. Dr. Tang received his Ph.D. degree in Biochemistry from the University of British Columbia.

Dr. Tang received his Ph.D. degree from the University of British Columbia.

Chief Technology Officer

Dr. Pan is the CTO at TandemAI. He brings over 20 years of experience applying molecular simulation to fundamental scientific questions and drug discovery

Previously, Dr. Pan was a Senior Research Scientist for over 12 years at D.E. Shaw Research. At D. E. Shaw, Dr. Pan led the development of free energy calculations and novel enhanced sampling methods and their application to challenging drug targets, and played a major role in fundamental biophysics research.

Dr. Pan earned a Ph.D. in Chemistry from the University of California, Berkeley, and an A.B. in Chemistry and Physics from Harvard University, where he graduated magna cum laude. He was subsequently an NIH NRSA Postdoctoral Fellow at the University of Chicago.

Chief Scientific Officer

Steve Swann is Chief Scientific Officer at TandemAI. He brings nearly 20 years of research and research leadership experience in medicinal and computational chemistry at large and emerging pharmaceutical companies.

Previously, Dr. Swann served as Vice President of Medicinal Chemistry (US) at Exscientia. He joined Exscientia from Silicon Therapeutics, a physics-driven drug discovery company (now part of Roivant), where he held several research leadership positions of increasing responsibility, most recently Vice President Chemistry and Design. Prior to Silicon Therapeutics, Dr. Swann served at Takeda Pharmaceuticals, AbbVie, and DuPont Pharmaceuticals.

Dr. Swann holds a B.S. in Chemistry from Saint Francis University and a Ph.D. in Chemistry from the University of Delaware.

Chief Business Officer

Alessandro Monge is Chief Business Officer at TandemAI. He brings more than 20 years of experience in developing and deploying marketing strategies for computational technologies.

Dr. Monge joined TandemAI from Iktos, a company applying AI to small molecule drug design, where he built the company’s US operations and closed research collaboration and technology licensing agreements with companies including Pfizer, Alkermes, Blueprint Medicines and Kadmon. Since 2018, he has served as a strategic business advisor to Nanome, the leader in collaborative structure-based design through virtual reality technologies. Prior to Iktos, he served as Vice President, Strategic Business, at Schrödinger, where he managed key client relationships, and initiated and expanded the adoption of products and services. Previously, he was Co-founder, President and CEO of ProCeryon Biosciences, a company developing and commercializing in silico protein structure prediction technology.

Dr. Monge received a B.S. degree (Laurea) Magna Cum Laude in Physics from the University of Pavia (Italy) and earned a Ph.D. in Theoretical Physics from the Rockefeller University.